STOCK ALERT: Rosen Law Firm Continues to Investigate Securities Claims Against Zosano Pharma Corporation
NEW YORK, May 09, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces that it is continuing to investigate potential securities claims on behalf of shareholders of Zosano Pharma Corporation resulting from allegations that Zosano Pharma may have issued materially misleading business information to the investing public.
On January 27, 2015, Zosano Pharma sold 6.5 million shares of stock in its initial public offering (the “IPO”), raising over $71 million in new capital. Upon news of the alleged failure of Zosano Pharma’s lead osteoporosis drug program to reach commercial viability, shares of Zosano Pharma fell dramatically in value from its IPO price of $11 per share and closed at $2.35 per share on April 7, 2016.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Zosano Pharma investors. If you purchased shares of Zosano Pharma, please visit the firm’s website at http://rosenlegal.com/cases-876.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 lrosen@rosenlegal.com pkim@rosenlegal.com kchan@rosenlegal.com www.rosenlegal.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
